CA2021500A1 - Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique - Google Patents

Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique

Info

Publication number
CA2021500A1
CA2021500A1 CA2021500A CA2021500A CA2021500A1 CA 2021500 A1 CA2021500 A1 CA 2021500A1 CA 2021500 A CA2021500 A CA 2021500A CA 2021500 A CA2021500 A CA 2021500A CA 2021500 A1 CA2021500 A1 CA 2021500A1
Authority
CA
Canada
Prior art keywords
peripheral blood
blood lymphocytes
stimulating proliferation
subpopulations
starting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2021500A
Other languages
English (en)
Other versions
CA2021500C (fr
Inventor
Teruaki Sekine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23515405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2021500(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of CA2021500A1 publication Critical patent/CA2021500A1/fr
Application granted granted Critical
Publication of CA2021500C publication Critical patent/CA2021500C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002021500A 1989-07-21 1990-07-19 Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique Expired - Lifetime CA2021500C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38394289A 1989-07-21 1989-07-21
US383,942 1989-07-21

Publications (2)

Publication Number Publication Date
CA2021500A1 true CA2021500A1 (fr) 1991-01-22
CA2021500C CA2021500C (fr) 1995-06-13

Family

ID=23515405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002021500A Expired - Lifetime CA2021500C (fr) 1989-07-21 1990-07-19 Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique

Country Status (7)

Country Link
EP (1) EP0409655A3 (fr)
JP (1) JP3056230B2 (fr)
AU (1) AU633940B2 (fr)
CA (1) CA2021500C (fr)
GR (1) GR1001034B (fr)
IE (1) IE902662A1 (fr)
ZA (1) ZA905735B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2981486B2 (ja) * 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
EP0578740A4 (en) * 1991-04-05 1995-12-20 Univ Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
WO1995032729A1 (fr) * 1994-05-31 1995-12-07 Augusto Carlos Ochoa Stimulation anti-cd3 a court terme des lymphocytes destinee a en accroitre l'activite in vivo
JP3381224B2 (ja) * 1996-04-17 2003-02-24 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング リンパ球を生産し、そして増加させる方法
US6511848B2 (en) 1996-04-17 2003-01-28 Winfried Albert Process for producing and multiplying lymphocytes
JP4186013B2 (ja) * 1996-07-15 2008-11-26 暉彬 関根 ウイルス感染症の治療・予防剤、その調製方法
SE511143C2 (sv) 1997-12-30 1999-08-09 Sca Hygiene Paper Ab Metod att framställa ett papper uppvisande en tredimensionellt mönster
JP2001354575A (ja) 2000-06-09 2001-12-25 Human Tekku:Kk 癌の再発予防法および癌の再発予防用活性化リンパ球を含む製剤、ならびにそれらの細胞の凍結および加工委・受託システム
JP4917201B2 (ja) * 2000-12-04 2012-04-18 株式会社リンフォテック 臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤、臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤、臍帯血移植後の腫瘍および各種感染症の予防・治療用製剤ならびに臍帯血移植後の移植臍帯血幹細胞の生着促進用製剤の製造方法。
US20040086492A1 (en) * 2001-03-05 2004-05-06 Hideo Yanai Method of treating tumor and consignment system of proliferating and processing activated lymphocytes to be used in parallel to pdt
DE10120505A1 (de) * 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
ATE491021T1 (de) 2002-03-25 2010-12-15 Takara Bio Inc Verfahren zur produktion eines zytotoxischen lymphozyten
JP4562353B2 (ja) * 2002-04-08 2010-10-13 株式会社リンフォテック Ｈｌａ一致他人由来活性化リンパ球を含有してなる腫瘍・感染症および自己免疫疾患の予防・治療用製剤
US20070025961A1 (en) 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
DE602004025591D1 (de) 2003-08-22 2010-04-01 Takara Bio Inc Verfahren zur herstellung zytotoxischer lymphozyten
JP2006143709A (ja) * 2004-10-20 2006-06-08 Lymphotec:Kk 薬剤耐性原生生物感染症の治療もしくは予防用製剤、該製剤の調製用キットおよび調製方法、薬剤耐性原生生物感染症の治療方法
CN101243187B (zh) * 2005-08-17 2012-07-11 宝生物工程株式会社 淋巴细胞的制备方法
EP2032719A2 (fr) * 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Procédé pour identifier si un patient est reactif ou non a l'immunotherapie
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
US20190345536A1 (en) * 2016-12-27 2019-11-14 Sumitomo Chemical Company, Limited Detection method for chromosomal abnormalities and method for evaluating inducibility
BR112020015512A2 (pt) 2018-02-01 2021-01-26 Nkmax Co., Ltd. método de produção de células exterminadoras naturais e composição para tratamento de câncer
EP4070855A4 (fr) 2019-11-01 2024-04-03 Kyoto Prefectural Public University Corporation Récepteur d'anticorps de lympocyte b et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE82588T1 (de) * 1986-04-28 1992-12-15 Endotronics Inc Zuchtverfahren fuer leukocyten.
WO1988000970A2 (fr) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Procede de culture de leucocytes
DE3634017A1 (de) * 1986-10-06 1988-04-14 Max Planck Gesellschaft Verfahren zur aktivierung und vermehrung von t-zellen, insbesondere von deren subpopulationen
WO1990004633A1 (fr) * 1988-10-21 1990-05-03 Brigham And Women's Hospital ACTIVATION ET CROISSANCE DE LYMPHOCYTES HUMAINS INFILTRANT LES TUMEURS AU MOYEN D'ANTICORPS ANTI-CD3 OU ANTI-TcR

Also Published As

Publication number Publication date
AU5918290A (en) 1991-01-24
EP0409655A3 (en) 1992-04-15
CA2021500C (fr) 1995-06-13
JPH0380076A (ja) 1991-04-04
JP3056230B2 (ja) 2000-06-26
EP0409655A2 (fr) 1991-01-23
ZA905735B (en) 1992-03-25
GR1001034B (el) 1993-03-31
AU633940B2 (en) 1993-02-11
IE902662A1 (en) 1991-02-27
GR900100551A (fr) 1991-12-10

Similar Documents

Publication Publication Date Title
CA2021500A1 (fr) Methode pour stimuler la proliferation de lymphocytes dans le sang peripherique
HUT64595A (en) Method for producing mammalian cytokine, il-11
AU1551888A (en) Intercellular adhesion molecules and their binding ligands
NO953548D0 (no) Immobilisering og separering av celler og andre partikler
MX9703681A (es) Metodo para hacer una coleccion de compuestos.
DE3177286D1 (de) Genetisch modifizierte mikroorganismen fuer die massenherstellung amylolytischer enzyme und verfahren zu deren herstellung.
CA2198633A1 (fr) Procede de developpement rapide ("rem") pour la propagation des lymphocytes t in vitro
GR3023723T3 (en) Method of activating cytolytic activity of lymphocytes using anti-CD28 antibody
EP2298804A3 (fr) Production d'anticorps monoclonaux par transformation par EBV de lymphocytes B
DK0716685T3 (da) Granulat indeholdende flere enzymer
EP0365837A3 (fr) Molécules d'adhésion intercellulaire et leurs ligands de liaison
MX9605088A (es) Metodos para proliferar y diferenciar celulas b y sus usos.
EP0291728A3 (fr) Production d'interféron immun et son ARN-m
BG102513A (en) Method for the diagnostics and the treatment of flat cellular cancer
AU580949B2 (en) Cell culture apparatus and process using an immobilized cell composite
EP0160486A3 (en) Monoclonal antibodies
AU7913887A (en) Method for the removal of undesired cells from human lymphocyte populations, application of the method in monoclonal antibody production and kit therefor
ES8501530A1 (es) Metodo de ensayo de anticuerpos.
DE69012105D1 (en) Proliferation von cd4-lymfocyten.
EP0267615A3 (fr) Compositions et méthodes pour le traitement du cancer utilisant d'une part un anticorps monoclonal contre le ganglioside GD3 et d'autre part l'IL-2
ATE48442T1 (de) Erwachsene-t-zellen-leukaemie verbundene zellinien, verfahren zur herstellung dieser linie und gegenserum.
WO1987007640A1 (fr) Procede de preparation de neuraminidase
FR2490672B1 (fr) Microemulsion de substances nutritives, assimilables par des microorganismes, son procede de preparation, et ses applications
AU6659390A (en) Methods for utilizing cell lines which lack human class ii histocompatibility antigens
WO1988000836A3 (fr) Immunosuppresseur et son procede de fabrication

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202